What did @sweetcakes_72 actually say?
Honestly, the transcript here is nearly empty. The only captured line is a prayer-like statement: "I pray you get everything you didn't I pray God." That is not a health claim. It is a caption and hashtag-driven post, so what we can actually analyze comes from the caption itself, not spoken words. The creator reports losing 4 pounds in one week on what appears to be retatrutide, while also using GHK-Cu, and notes feeling "not feeling any different" and "eating reg" (regularly, presumably without significant appetite changes). That is the sum of verifiable content here.
This matters because most of the factual surface area is in text overlays and captions, not in any evaluable verbal claim. We are working with a self-reported weight loss figure and a subjective absence of side effects or noticeable effects from GHK-Cu. Neither is a strong claim, but both are worth examining.
Does the science back this up?
On retatrutide: yes, early-phase data supports meaningful weight loss, but four pounds in one week is almost certainly water weight and glycogen depletion, not fat. On GHK-Cu feeling like nothing: also consistent with the evidence, because the human data on GHK-Cu is thin.
Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors. In the Phase 2 trial published by Jastreboff et al. (2023, New England Journal of Medicine), participants at higher doses lost up to 17.5 percent of body weight over 24 weeks. That is a meaningful signal. However, week-one losses on GLP-1 class drugs are heavily driven by reduced fluid retention and glycogen stores, not adipose tissue reduction. The creator saying they are "eating reg" while losing 4 pounds suggests either appetite suppression they are not consciously registering, or early-phase water weight shifts. Possibly both.
GHK-Cu (copper peptide) has some cell-culture and animal data suggesting roles in wound healing and skin remodeling, but a 2018 review by Pickart and Margolina in Biomedicines found human clinical evidence is limited and largely confined to topical applications. Systemic injectable GHK-Cu for "longevity or optimization" has essentially no randomized controlled trial support in humans.
What did they get wrong (or right)?
They got the retatrutide weight-loss direction right. The drug does produce weight loss, and early movement on the scale within a week is consistent with published data. Credit where it is due.
What is missing, and this is a real problem, is any acknowledgment that retatrutide is not FDA-approved. It is still in Phase 3 trials as of mid-2024. Any version someone is currently injecting is a compounded or gray-market peptide, not the investigational drug used in Eli Lilly's trials. Those are not the same thing, and assuming equivalent safety or efficacy based on trial data is a stretch.
The GHK-Cu "not feeling any change" report is actually honest and consistent with what the science would predict. There is no robust evidence that injectable GHK-Cu produces noticeable short-term subjective effects. The creator is not overselling it, which is refreshing compared to most peptide content online. But the absence of a felt effect does not mean absence of biological activity, and it also does not mean it is doing anything useful.
What should you actually know?
If you are watching peptide content on TikTok, the gap between what trial participants receive and what is being sold through online compounders or gray-market vendors is not a small gap. It is a regulatory canyon. Retatrutide has shown real promise in controlled settings, but "real promise in a Phase 2 trial" and "safe for you to self-inject a compounded version" are completely different statements.
A few things worth knowing before going down this path:
- Retatrutide is not FDA-approved. Any product labeled as retatrutide sold outside a clinical trial is compounded or sourced from unregulated suppliers. Purity, dosing accuracy, and sterility are not guaranteed.
- GLP-1 class drugs, including retatrutide, carry real side effect profiles: nausea, vomiting, gastroparesis risk, and potential pancreatitis. Week one feeling fine is not week eight data.
- GHK-Cu human systemic data is essentially nonexistent in peer-reviewed literature. It is not dangerous in the way some peptides are, but it is not proven effective either.
- Four pounds in week one on any weight-loss intervention is almost never four pounds of fat. Caloric math alone makes that unlikely in most cases.
- Always consult a licensed provider before starting any peptide protocol. A TikTok update, including this one, is not medical guidance.